Seven Eight Capital LP Grows Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Seven Eight Capital LP increased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 195.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,739 shares of the company’s stock after buying an additional 35,568 shares during the quarter. Seven Eight Capital LP owned 0.06% of Dyne Therapeutics worth $1,896,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in DYN. Trexquant Investment LP purchased a new position in Dyne Therapeutics during the fourth quarter valued at $304,000. Rafferty Asset Management LLC lifted its position in shares of Dyne Therapeutics by 17.7% during the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after buying an additional 24,632 shares in the last quarter. Commodore Capital LP bought a new position in shares of Dyne Therapeutics during the 4th quarter valued at approximately $11,970,000. Frazier Life Sciences Management L.P. purchased a new stake in Dyne Therapeutics in the 4th quarter worth approximately $15,758,000. Finally, Octagon Capital Advisors LP raised its stake in Dyne Therapeutics by 14.4% during the 4th quarter. Octagon Capital Advisors LP now owns 792,945 shares of the company’s stock worth $10,546,000 after acquiring an additional 100,000 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In other news, COO Susanna Gatti High sold 29,787 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $35.01, for a total value of $1,042,842.87. Following the sale, the chief operating officer now directly owns 148,792 shares in the company, valued at approximately $5,209,207.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, COO Susanna Gatti High sold 29,787 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $35.01, for a total value of $1,042,842.87. Following the completion of the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at approximately $5,209,207.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Cox bought 32,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was bought at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The disclosure for this purchase can be found here. 20.77% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on DYN. StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Morgan Stanley increased their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus raised their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Piper Sandler upped their price objective on Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Finally, Guggenheim lifted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Trading Down 0.8 %

Shares of Dyne Therapeutics stock opened at $34.34 on Thursday. The firm has a market cap of $3.00 billion, a PE ratio of -8.65 and a beta of 1.07. The stock has a 50 day moving average of $41.38 and a 200 day moving average of $33.47. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. As a group, equities research analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.